Readily isolated bispecific antibodies with native immunoglobulin format

US8586713B2 · kind B2 · utility

Assignee

• REGENERON PHARMACEUTICALS, INC. · US

Inventors

• Samuel Davis · New York, US
• Eric Smith · New York, US
• Douglas MacDonald · New York, US
• Kara Olson · White Plains, US

Key dates

• Filing date: Jun 25, 2010
• Grant date: Nov 19, 2013
• Expiry date: Jul 5, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/76
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A bispecific antibody format providing ease of isolation is provided, comprising immunoglobulin heavy chain variable domains that are differentially modified in the CH3 domain, wherein the differential modifications are non-immunogenic or substantially non-immunogenic with respect to the CH3 modifications, and at least one of the modifications results in a differential affinity for the bispecific antibody for an affinity reagent such as Protein A, and the bispecific antibody is isolable from a disrupted cell, from medium, or from a mixture of antibodies based on its affinity for Protein A.